There's new research linking senolytics to helping slow down Alzheimer's progression. Here's how and what experts have to say ...

Some neurologists and a consumer watchdog worry that an Eli Lilly–affiliated direct-to-consumer telehealth platform for Alzheimer’s could lead to misdiagnosis or unnecessary treatment.

An extended study after a primary trial supports using the anti-amyloid drug lecanemab (Leqembi) for up to 36 months in ...

According to the authors, the research opens up new possibilities for developing the next generation of ChE inhibitors that ...

Share on PinterestRecent research emphasizes the potential role of viral infections and over-the-counter medication in dementia risk. Design by MNT; Photography by alvaro gonzalez/Getty Images, Guido ...

SAN DIEGO -- Biomarker and cognitive data supported treatment with the anti-amyloid agent lecanemab (Leqembi) for up to 36 ...

Researchers have developed a blood test that can not only help diagnose Alzheimer’s disease, but also provide information to doctors on how far the disease has progressed.

Delve into how the biotech industry is pivoting from the amyloid hypothesis to find new Alzheimer's disease treatments.

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited ...

As a result, he said a lot of companies had refused to host Vance ahead of her visit and there was talk of more anti-American protests on the island, which has in recent weeks seen some of the ...